Cancer Support Stack
Supporting the "terrain" — strengthening healthy cells so treatments can stay on track.
Stack Overview
About This Stack
Thymosin α-1, GHK-Cu, and SS-31 form this adjunctive oncology support combination. Thymosin α-1 has clinical use in cancer by enhancing tumor-fighting immunity and reducing chemo-induced immune suppression. GHK-Cu (copper peptide) exhibits anti-tumorigenic effects in some studies (reduces cancer cell adhesion, though primarily known for skin repair) and supports tissue repair such as oral mucositis healing. SS-31 mitigates mitochondrial damage from chemo, protecting heart and nerves. Each is used with oncologist consent, focusing on quality of life and resilience. Emer's doctrine frames this as supporting the "terrain" — strengthening healthy cells so treatments can stay on track.
Composition
What's In This Stack
Enhances tumor-fighting immunity and reduces chemo-induced immune suppression. Improves outcomes and lowers infection risk during chemo. Used to improve response to chemotherapy by immune enhancement — supporting T-cell and NK-cell function during immunosuppressive treatment.
Dose: 1.6 mg SC 2×/week (during and around chemotherapy cycles)
Route: Subcutaneous
Exhibits anti-tumorigenic effects in some studies (reduces cancer cell adhesion). Primarily used for tissue repair in oncology context: oral mucositis healing, improving wound healing after surgeries, skin repair. Collagen-organizing peptide — signals fibroblasts to lay down parallel, elastic collagen rather than disordered scar tissue.
Dose: 200 mcg IV or 100–200 mcg SC injectable, or topical application
Route: Subcutaneous, IV, or topical
Synthetic tetrapeptide that targets the inner mitochondrial membrane — binding to cardiolipin and improving electron transport chain efficiency. Mitigates mitochondrial damage from cardiotoxic chemo drugs (to preserve cardiac function). A mitochondrial antioxidant and stabilizer that restores redox balance and reduces reactive oxygen species. Used for patients on cardiotoxic chemo drugs.
Dose: 5–10 mg SC daily in 4–12 week cycles
Route: Subcutaneous (daily injections)
Protocol
Treatment Protocol
Used with oncologist consent and oversight. Ta1 1.6 mg SC 2×/week during chemotherapy cycles or between cycles. GHK-Cu topical for mucositis/skin healing, SC injectable for deeper tissue repair. SS-31 SC daily for patients on cardiotoxic regimens. Focused on quality of life and resilience — not a standalone cancer treatment. Monitoring: CBC, cardiac function (if SS-31), inflammatory markers, and patient-reported quality of life measures.
Patient Fit
Ideal For
- Cancer patients undergoing chemotherapy (adjunctive support)
- Patients with chemo-induced immunosuppression
- Patients with cardiotoxic chemo drugs (SS-31 for cardiac protection)
- Post-surgical oncology patients needing tissue repair
- Patients seeking quality-of-life improvement during cancer treatment
Results
Clinical Outcomes
Oncology integrative protocols: Ta1 injections improve outcomes and lower infection risk during chemo. GHK-Cu for tissue repair (e.g. oral mucositis healing, improving wound healing after surgeries). SS-31 for patients on cardiotoxic chemo drugs (to preserve cardiac function). Each is used with oncologist consent, focusing on quality of life and resilience. Emer frames this as supporting the "terrain" — strengthening healthy cells so treatments can stay on track.
Begin Your RECODEX™ Protocol
All peptide stacks are physician-supervised and custom-tailored.
Request Consultation
